drugset
drugset / Trial / NCT06547957

A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

NCT06547957 ↗

Phase 1 Active not recruiting 55 enrolled iTeos Therapeutics
Non-randomizedSequentialOpen-labelTreatment

Summary

APT-008 is an open-label, Phase I/Ib, dose escalation and expansion cohort study to evaluate the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and preliminary efficacy of EOS301984 as monotherapy and in combination with other anticancer therapies in participants with advanced solid tumors.

Timeline

Start
2023-07-07
Primary completion
2025-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject EOS301984 Unknown — —

Indications

cancer